Bulk Pharmaceutical API Sources for HYDRODIURIL

Bulk Pharmaceutical API Sources for HYDRODIURIL

Vendor	Vendor Homepage	Vendor Sku	API Url
Specs		AF-614/30832002
Sigma-Aldrich		H4759_SIAL
Sigma-Aldrich		H2910_SIAL
Vitas-M Laboratory		STK315354
TCI (Tokyo Chemical Industry)		H1274
Molport		MolPort-000-144-465

Bulk Active Pharmaceutical Ingredient (API) Sources for: HYDRODIURIL

Last updated: July 30, 2025

---

Introduction

Hydrodiuril, the trademarked name for hydrochlorothiazide (HCTZ), is a widely prescribed thiazide diuretic used primarily for hypertension and edema management. As a vital component in cardiovascular therapy, the quality, reliability, and legality of bulk Hydrochlorothiazide (API) sourcing directly impact pharmaceutical manufacturers and healthcare outcomes. This analysis details the global landscape of API sources—highlighting key suppliers, manufacturing regions, quality considerations, regulatory compliance, and supply chain stability.

---

Global Manufacturing Landscape of Hydrochlorothiazide API

1. Leading Countries in API Production

The primary regions responsible for hydroclorothiazide API manufacturing include:

• India: A dominant hub, contributing approximately 70% of global API production, India leverages a combination of cost-effective manufacturing, established chemical industry infrastructure, and flexible regulatory pathways. Major Indian API producers include Torrent Pharmaceuticals, Aurobindo Pharma, and Sun Pharma, which have extensive experience in synthesizing HCTZ adhering to international standards.

• China: With a substantial share, China specializes in bulk chemical manufacturing, offering competitive pricing and vast production capacities. Principal Chinese API producers such as Zhejiang Hisoar Pharmaceutical and Jiangsu Hengrui Medicine Co. have scaled up production, providing raw materials to global markets.

• Europe and the United States: While less dominant in volume, these regions emphasize high-quality, GMP-compliant manufacturing, often serving as sources for finished APIs with rigorous regulatory oversight. Companies like Novartis and BASF have manufacturing sites producing HCTZ compliant with strict regulatory standards.

2. Manufacturing Processes

Hydrochlorothiazide synthesis mainly involves chlorosulfonation of chlorothiazide followed by sulfonamide formation. Key manufacturing differences focus on process optimization, impurities management, and compliance with Good Manufacturing Practice (GMP). The complexity of synthesis and purification influences cost and scalability, impacting supply reliability.

---

Key API Suppliers and Vendors

1. Indian API Manufacturers

• Aurobindo Pharma: A leading supplier with WHO-GMP and US FDA approvals; supplies high-purity HCTZ APIs suitable for global markets.
• Sun Pharma: Provides comprehensive API portfolios, including Hydrochlorothiazide, with consistent quality and competitive pricing.
• Torrent Pharmaceuticals: Known for robust manufacturing capabilities and adherence to international regulatory standards.

2. Chinese API Vendors

• Zhejiang Hisoar Pharmaceutical: Supplies high-quality HCTZ APIs, often meeting or exceeding international pharmacopoeial standards.
• Jiangsu Hengrui Medicine Co.: Established for large-scale chemical synthesis with state-of-the-art facilities and quality systems.

3. Other Notable Suppliers

• EMD Millipore (Merk KGaA): Specializes in pharmaceutical-grade APIs and intermediates, including Hydrochlorothiazide, with a focus on quality and regulatory compliance.
• Deyang Gean Pharmaceutical Co.: Chinese producer emphasizing high purity and scalable manufacturing.

---

Regulatory Standards and Quality Considerations

Manufacturers and buyers must prioritize suppliers compliant with:

• USP (United States Pharmacopeia)
• EP (European Pharmacopoeia)
• JP (Japanese Pharmacopoeia)
• GMP Certification: Ensures consistent quality, purity, and safety.
• FDA Approval: For APIs intended for the US market, FDA registration and inspection history are critical indicators of compliance.

Impurities and Specifications:
High-quality sources adhere to impurity thresholds set by pharmacopoeias, including limits for residual solvents, heavy metals, and process-related impurities. Robust analytical and quality control methodologies reduce risks of cross-contamination or adulteration.

---

Supply Chain Considerations and Risks

1. Geopolitical Factors:
   Trade policies, tariffs, and political instability in key manufacturing nations like India and China can affect supply continuity.

2. Capacity Constraints:
   Amid COVID-19 disruptions, several API producers experienced bottlenecks, prompting diversification strategies.

3. Regulatory Environment:
   GMP compliance and inspection history influence supply reliability and market access.

4. Quality Certifications:
   Preference for suppliers with international certifications (e.g., ISO, GMP, WHO-GMP) minimizes quality risks and ensures regulatory adherence.

---

Emerging Trends and Future Outlook

• Vertical Integration: Leading pharmaceutical companies increasingly integrate API manufacturing to control quality and supply.
• Supply Diversification: Companies diversify suppliers across regions to mitigate risks associated with concentration in India and China.
• Biotechnological Advancements: While chemical synthesis remains dominant, research into biotechnological routes for HCTZ is minimal but could influence future supply dynamics.
• Regulatory Scrutiny: Stricter import/export policies and emphasis on compliance will continue to shape sourcing strategies.

---

Conclusion

Reliable sourcing of Hydrochlorothiazide API is vital for pharmaceutical production and patient safety. Indian and Chinese manufacturers dominate the global landscape, offering a balance of cost-effective and regulatory-compliant options. European and American suppliers serve high-end markets with strict quality requirements. Ensuring supply chain resilience involves balancing cost, quality, regulatory compliance, and geopolitical stability.

---

Key Takeaways

• India and China are the primary API manufacturing hubs for Hydrochlorothiazide, accounting for the bulk of global production.
• Suppliers with GMP, WHO-GMP, or FDA approvals provide higher confidence in quality and regulatory compliance.
• Diversifying API sources reduces risk associated with geopolitical, regulatory, or capacity disruptions.
• Continuous monitoring of supplier compliance, capacity expansions, and geopolitical developments is crucial for reliable procurement.
• Investing in quality assurance processes and supplier audits enhances supply chain integrity and regulatory adherence.

---

FAQs

1. What are the leading countries supplying Hydrochlorothiazide API globally?
India and China dominate the Hydrochlorothiazide API market, providing cost-effective, scalable, and high-quality options. European and US manufacturers serve niche markets with strict regulatory standards.

2. How can I verify the quality of Hydrochlorothiazide API suppliers?
Verify suppliers' GMP, ISO, and regulatory certifications (e.g., FDA approval). Review analytical test reports, impurity profiles, and conduct supplier audits when possible.

3. Are there any emerging operators in Hydrochlorothiazide API manufacturing?
While Indian and Chinese manufacturers continue to expand capacity, new entrants from Southeast Asia and Eastern Europe are emerging, emphasizing quality and regulatory compliance.

4. What are common risks associated with API sourcing for Hydrochlorothiazide?
Supply disruptions due to geopolitical issues, capacity limitations, quality non-compliance, and regulatory actions pose significant risks.

5. How are regulatory standards impacting API sourcing strategies?
Strict adherence to GMP, pharmacopoeial standards, and regional regulations influence supplier selection. Regulatory audits and certifications are increasingly mandatory for market access.

---

References

[1] U.S. Pharmacopeia, Hydrochlorothiazide Monograph.
[2] European Pharmacopoeia, Hydrochlorothiazide Monograph.
[3] Global API Industry Reports, IQVIA & CPhI Reports.
[4] Pharmaceutical Regulatory Filings, FDA and EMA databases.